| 1 Pain (0‐100 mm VAS) change between baseline and 45 to 52 weeks post‐injection |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2 Lequesne Index (0‐100 modified scale) change between baseline and 45 to 52 weeks post‐injection |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3 Patient global assessment (0‐100 mm VAS) change between baseline and 45 to 52 weeks post‐injection |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4 Percentage of painful days (0‐100 mm VAS) change between baseline and 45 to 52 weeks post‐injection |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5 Patient assessment of treatment efficacy (no. of patients rating very good or good versus mod, bad or very bad |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6 Joint space width (percentage of progressors: joint space narrowing greater than 0.5 mm) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7 Safety: total withdrawals overall |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 8 Safety: withdrawals due to inefficacy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9 Safety: number of withdrawals due to adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 10 Safety: number of patients reporting knee pain during or after IA injection |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 11 Safety: number of patients reporting diarrhoea |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
